Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-up of rasagiline after ADAGIO in Parkinson's disease
NL-OMON36779Phase 4Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2010
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rasagiline in Parkinson's disease (PD), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Long-term benefit of early-start versus delayed-start rasagiline and Long-term effects of continued rasagiline treatment. Started Jan 2010; status: recruiting.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON36779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36779.